VISEN Pharmaceuticals
Company Profile
Business description
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
Contact
69 Jiuzhang Road
Suite 3-108, Floor 3, Building B
Hengtai Lixiang Chuangxin Tower
Suzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
82
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,755.40 | 44.00 | -0.50% |
| CAC 40 | 7,981.76 | 5.73 | -0.07% |
| DAX 40 | 24,400.65 | 92.73 | 0.38% |
| Dow JONES (US) | 49,363.88 | 322.24 | -0.65% |
| FTSE 100 | 10,330.55 | 6.80 | 0.07% |
| HKSE | 25,641.44 | 156.41 | -0.61% |
| NASDAQ | 25,870.71 | 220.02 | -0.84% |
| Nikkei 225 | 59,795.28 | 755.31 | -1.25% |
| NZX 50 Index | 12,854.33 | 119.99 | -0.92% |
| S&P 500 | 7,353.61 | 49.44 | -0.67% |
| S&P/ASX 200 | 8,530.90 | 42.20 | -0.49% |
| SSE Composite Index | 4,151.89 | 17.65 | -0.42% |